1 One Year Post Exclusivity Adverse Event Review: Fentanyl Transdermal System Pediatric Subcommittee of the Anti-infective Drugs Advisory Committee Meeting.

Slides:

Advertisements

Similar presentations

A Retrospective Review Investigating the Feasibility of Acupuncture as a Supportive Care Agent in Children with Cancer Kathy Taromina, MS, LAc, Diane Rooney,

Advertisements

Dermatologic and Ophthalmic Drugs Advisory Committee July 12, Clinical Wrap-Up Denise Cook, M.D. Medical Officer Division of Dermatology and Dental.

Edward P. Sloan, MD, MPH, FACEP Conducting Successful EM Resident Research: Working with Databases.

Key dosing points: Begin a bowel regimen when opioid therapy is initiated (senna + docusate). For CHRONIC pain, use a scheduled medication regimen. ( ex:

Sublingual Buprenorphine and Pain

Anesthetic and Life Support Drugs, and Drug Safety and Risk Management Advisory Committees, November 13, 2008 Outpatient Drug Utilization Trends for Oxycodone.

1 Drug Utilization for Immediate- and Modified Release Opioids in the U.S. Gianna C. Rigoni, Pharm.D., M.S. Epidemiologist Division of Surveillance, Research.

FDA Perspective Sally Loewke, M.D. Acting Division Director

RACIAL DISPARITIES IN PRESCRIPTION DRUG UTILIZATION AN ANALYSIS OF BETA-BLOCKER AND STATIN USE FOLLOWING HOSPITALIZATION FOR ACUTE MYOCARDIAL INFARCTION.

Opioid Call History Utah Poison Control Center Marty Malheiro, MS, CHES Coordinator, Outreach Education.

Optimal Pain Management for ED Patients: Issues in 2004 Edward P. Sloan, MD, MPH, FACEP Professor Department of Emergency Medicine University of Illinois.

Mr. Beerbower McHenry High School

1 One Year Post Exclusivity Adverse Event Review: Atovaquone-Proguanil Pediatric Advisory Committee Meeting February 14, 2005 Alan M. Shapiro, MD, PhD,

1 One Year Post-Exclusivity Adverse Event Review: Ertapenem Pediatric Advisory Committee Meeting November 16, 2006 Alan M. Shapiro, MD, PhD, FAAP Medical.

Prescription Drug Abuse Sharon Hertz, M.D. Medical Officer Division of Anesthetic, Critical Care and Addiction Drug Products Food and Drug Administration.

The Risks of Cough/Cold Preparations to Young Children Michael Shannon, MD, MPH Children’s Hospital Boston Harvard Medical School.

Abuse Liability of Hydromorphone Extended Release Capsules Silvia N. Calderon, Ph.D. Controlled Substance Staff Center for Drug Evaluation and Research.

1 One Year Post Exclusivity Adverse Event Review as Mandated by the Best Pharmaceuticals for Children Act Presented at the Psychopharmacologic Drugs Advisory.

DSaRM Advisory Committee May 18, 2005 Active Surveillance for Drug Safety Signals: Past, Present, and Future Mary Willy, Ph.D. Division of Drug Risk Evaluation.

Adverse Event Tracking as mandated by the Best Pharmaceuticals for Children Act Dr. Solomon Iyasu Medical Team Leader Division of Pediatric Drug Development.

1 One Year Post Exclusivity Adverse Event Review: Ofloxacin Ophthalmic Pediatric Advisory Committee Meeting September 15, 2004 Hari Cheryl Sachs, MD, FAAP.

1 One Year Post Exclusivity Adverse Event Review: Alendronate Pediatric Advisory Committee Meeting September 15, 2004 Hari Cheryl Sachs, MD, FAAP Medical.

Snapshot of IMS LifeLink Claims Database 10% Random Sample

1 Kepivance™ (Palifermin) Basis for Approval and Pediatric Studies Kepivance™ (Amgen) Approved 12/15/04 Joseph E. Gootenberg, M.D. Office of Oncology Drug.

Pediatric Advisory Committee April 11, Update to the Committee: Oxybutynin Central Anticholinergic Effects Pediatric Advisory Committee Meeting.

1 One Year Post-Exclusivity Adverse Event Review: Tolterodine Pediatric Advisory Committee Meeting June 29, 2005 Lawrence Grylack, MD Medical Officer Division.

1 Alcohol and Substance Abuse Council of Jefferson County, Inc. 167 Polk Street, Suite 320 Watertown, New York Voice: ; Fax: ;

Joint Dermatologic and Ophthalmic Drugs & Drug Safety and Risk Management Advisory Committee February 26 & 27, Overview Isotretinoin Pregnancy Exposures:

1 Update to Post Exclusivity Pediatric Adverse Event Review: Simvastatin Pediatric Advisory Committee Meeting November 16, 2006 Jean Temeck, MD, Acting.

Pediatric Advisory Committee Meeting September 15, 2004

1 One Year Post Exclusivity Adverse Event Review: Fexofenadine Pediatric Subcommittee of the Anti-infective Drugs Advisory Committee Meeting June 9, 2004.

1 One Year Post Exclusivity Adverse Event Review: Topotecan Pediatric Subcommittee of the Anti-infective Drugs Advisory Committee Meeting June 9, 2004.

1 One Year Post-Exclusivity Adverse Event Review: Paricalcitol, Zolmitriptan, Dorzolamide, and Leflunomide Pediatric Advisory Committee Meeting June 29,

1 One Year Post Exclusivity Adverse Event Review Update: Orlistat Pediatric Advisory Committee Meeting April 11, 2007 Hari Cheryl Sachs, MD, FAAP Medical.

Post-Marketing AE Reports of Topical Calcineurin Inhibitors Pediatric Advisory Subcommittee of the Anti-Infective Drugs Advisory Committee Marilyn R. Pitts,

1 One Year Post Exclusivity Adverse Event Review: Esmolol Pediatric Advisory Committee Meeting February 14, 2005 Lawrence Grylack, MD Medical Officer Division.

Study Finds Persons Who Fill Buprenorphine Prescriptions Have Higher Rates of Medical Conditions Associated with Pain and Comorbid Psychiatric Disorders.

1 One Year Post Exclusivity Adverse Event Review: Budesonide & Fluticasone Pediatric Advisory Committee Meeting September 15, 2004 Joyce Weaver, PharmD,

LEADING RESEARCH… MEASURES THAT COUNT Challenges of Studying Cardiovascular Outcomes in ADHD Elizabeth B. Andrews, MPH, PhD, VP, Pharmacoepidemiology and.

Prevalence of Polypharmacy Exposure Among Hospitalized Children in the United States Feudtner C, Dai D, Hexem KR, Luan X, Metjian TA. Prevalence of polypharmacy.

Buprenorphine Treatment for Opioid Dependence CESAR FAX U n i v e r s i t y o f M a r y l a n d, C o l l e g e P a r k A Weekly FAX from the Center for.

1 One Year Post Exclusivity Adverse Event Review: Carboplatin Pediatric Advisory Committee Meeting November 18, 2005 Susan McCune, M.D. Medical Officer.

1 One Year Post-Exclusivity Adverse Event Review: Meloxicam Pediatric Advisory Committee Meeting November 16, 2006 Hari Cheryl Sachs, MD, FAAP Medical.

1 One Year Post-Exclusivity Adverse Event Review: Insulin Aspart Recombinant Pediatric Advisory Committee Meeting November 16, 2006 Hari Cheryl Sachs,

Focus Area 17: Medical Product Safety Progress Review November 5, 2003.

INTRO TO THE DRUG CATEGORIES

1 One Year Post Exclusivity Adverse Event Monitoring as mandated by the Best Pharmaceuticals for Children Act Dr. Solomon Iyasu Medical Team Leader Dr.

AprepitantAprepitant Division of Gastrointestinal and Coagulation Drug Products Division of Gastrointestinal and Coagulation Drug Products Center for Drug.

1 One Year Post Exclusivity Adverse Event Review: Sumatriptan Pediatric Advisory Committee Meeting November 18, 2005 Susan McCune, M.D. Medical Officer.

1 One Year Post Exclusivity Adverse Event Review: Ciprofloxacin Pediatric Subcommittee of the Anti-infective Drugs Advisory Committee Meeting June 9, 2004.

Analgesics and Antipyretics

1 One Year Post Exclusivity Adverse Event Review: Venlafaxine Pediatric Subcommittee of the Anti-infective Drugs Advisory Committee Meeting June 9, 2004.

Zelnorm ® (tegaserod) Division of Gastrointestinal and Coagulation Drug Products Division of Drug Risk Evaluation Gary Della’Zanna, D.O., M.Sc., F.A.C.O.S.

Review Update: QT Prolongation with Citalopram and Escitalopram Pediatric Advisory Committee Meeting November 16, 2006 Prepared by M. Lisa Jones, MD Division.

1 One Year Post Exclusivity Adverse Event Review: Benazepril Pediatric Advisory Committee Meeting February 14, 2005 Lawrence Grylack, MD Medical Officer.

1 Update to Post-Exclusivity Pediatric Adverse Event Review: Oxybutynin Pediatric Advisory Committee Meeting November 16, 2006 Lisa Mathis, MD, Associate.

C-1 Safety Results S. aureus Bacteremia and Endocarditis Study Gloria Vigliani, M.D. Vice President, Medical Strategy Cubist Pharmaceuticals.

1 One Year Post Exclusivity Adverse Event Review: Glimepiride Pediatric Advisory Committee Meeting November 16, 2006 Hari Cheryl Sachs, MD, FAAP Medical.

1 Update to Post Exclusivity Pediatric Adverse Event Review: Atorvastatin Pediatric Advisory Committee Meeting November 16, 2006 Jean Temeck, MD, Acting.

1 One Year Post Exclusivity Adverse Event Review: Glyburide-Metformin Pediatric Advisory Committee Meeting February 14, 2005 Hari Cheryl Sachs, MD, FAAP.

1 Psychopharmacologic Drugs Advisory Committee and Pediatric Subcommittee of the Anti-Infective Drugs Advisory Committee February 2, 2004 Office of Drug.

Monthly Metrics Forum February 2014 Appropriate Testing for Children With Pharyngitis And Appropriate Treatment for Children With Upper Respiratory Infection.

Addressing the issue: Prescription Drug Misuse in North Carolina

Antibiotic use and bacterial complications following upper respiratory tract infections: a population based study.

Jessica E. Bates, Pharm.D. PGY-1 Pharmacy Resident

Opioid Prescribing CAPT Thomas Weiser, MD, MPH Medical Epidemiologist

Understanding the Opioid Epidemic

STOP! Safe Treatment of Pain

Prescription Drug Monitoring Program

ACUTE PAIN MANAGEMENT FOR EMS

Presentation transcript:

1 One Year Post Exclusivity Adverse Event Review: Fentanyl Transdermal System Pediatric Subcommittee of the Anti-infective Drugs Advisory Committee Meeting June 9, 2004 ShaAvhrée Buckman, MD, PhD, FAAP Medical Officer Division of Pediatric Drug Development Center for Drug Evaluation and Research Food and Drug Administration

2 Background Drug Information Moiety: Duragesic ® (Fentanyl Transdermal System) Therapeutic Category: Opioid Analgesic Sponsor: Johnson and Johnson, ALZA Indications: –Treatment of chronic pain (such as that of malignancy) that: cannot be managed by lesser means such as acetaminophen-opioid combinations, NSAIDs, or PRN dosing with short-acting opioids AND requires continuous opioid administration –Approved for pediatric use in children ≥ 2 years Original Market Approval: August 7, 1990 Pediatric Exclusivity Granted: January 29, 2003

3 Relevant Safety Labeling

4 Selected Additional Safety Labeling Duragesic ® should be prescribed only by persons knowledgeable in the continuous administration of potent opioids, in the management of patients receiving potent opioids for treatment of pain and in the detection and management of hypoventilation including the use of opioid antagonists

5 Drug Use Trends in Outpatient Settings: Fentanyl Transdermal System The total number of prescriptions dispensed for fentanyl transdermal systems in the U.S. have increased by 20% in the past 2 years (2/02 to 1/04), from 4.5 million in 2002 to 5.4 million in Top three prescribers in 2003 for fentanyl transdermal systems were: internal medicine, family practice, and anesthesiology. Approximately 0.2% of fentanyl transdermal system prescriptions dispensed were written by pediatricians. 1 1 IMS Health, National Prescription Audit Plus , On-Line, Feb 1999 – Jan 2004, Data Extracted March 2004

6 Drug Use Trends in Outpatient and Inpatient Settings: Fentanyl Transdermal System In the outpatient setting, children and adolescents have accounted for very few dispensed fentanyl transdermal system prescriptions over the past two years (2/02-1/04) –4,535 prescriptions (0.1%) (February 2002-January 2003) 1,2* –5,422 prescriptions (0.1%) (February 2003-January 2004) 1,2* In both the outpatient and inpatient settings, adolescents (ages years) accounted for over 60% of pediatric fentanyl transdermal system use over the last three years (2/01 to 1/04). 3 1 IMS Health, National Prescription Audit Plus , On-Line, Feb 1999 – Jan 2004, Data Extracted March AdvancePCS™, Dimension Rx, On-Line, Feb 2001 – Jan 2004, Data Extracted March Child Health Corporation of America TM : Pediatric Health Information System (PHIS), Jan Jun 2003 *Calculation based on application of proportions of pediatric fentanyl transdermal system prescription claims in AdvancePCS  to total number of prescriptions dispensed in IMS Health, National Prescription Audit Plus  to estimate number of fentanyl transdermal system prescriptions dispensed nationwide to pediatric population.

7 Drug Use Trends in Outpatient and Inpatient Settings: Fentanyl Transdermal Systems In the outpatient setting, the most frequent diagnoses associated with fentanyl transdermal systems in the pediatric, as well as the adult population, were associated with diseases of the musculoskeletal system and connective tissues. In the pediatric population, the most predominant musculoskeletal diagnosis was for spinal stenosis, followed by injuries involving fractured bones. 1 In the inpatient setting, the primary discharge diagnoses most frequently associated with billing of fentanyl transdermal systems during a hospitalization in the pediatric population were for chemotherapy encounters and various blood disorders, including sickle cell disease. 2 1 IMS Health, National Disease and Therapeutic Index™, CD_ROM, Feb 2001 – Jan 2004, Data Extracted Mar Premier Inc., Perspective™, Jan 2002 – Jun 2003, Data Extracted Apr 2004

8 Adverse Event Reports: Fentanyl Transdermal System 01/29/ /29/04 Total number of reports, all ages: –1917 (1468 U.S.) Pediatric reports: –8 unique cases (7 U.S.) –All with serious outcomes, including 5 deaths –Gender: Female (4), Male (4) –Age: 2-5 years (1), 6-11 years (2), years (5)

9 Pediatric Adverse Events in the One- Year Post-Exclusivity Period: Overdose (2) Drug abuser (2) Medication error (2) Coma Convulsions Death Drug level increased Drug withdrawal syndrome Nausea Urinary retention Vomiting Weight decreased Euphoric mood Cardiac arrest (2) Respiratory Arrest (2) Self-medication (2) Loss of consciousness Lung neoplasm Mydriasis Pelvic neoplasm Petechiae Pleural disorder Pulmonary congestion Pulmonary edema Toxicologic test abnormal Endocardial disease Labeled EventsUnlabeled Events Gastrointestinal obstruction Hemorrhage Hallucination Injury Anxious parent, Brain edema

10 Pediatric Adverse Events: Deaths (1 year post-exclusivity period; n=5) 1.8 year old female diagnosed with rhabdomyosarcoma, who died 2 months after being switched from the fentanyl transdermal system to IV morphine (Foreign) 2.9 year old male 2-days post tonsillectomy and adenoidectomy was treated with the fentanyl transdermal system 25  g patch with subsequent respiratory arrest resulting in death. Concomitant meds: Acetaminophen with codeine elixir (US) 3.4 year old female died from cardiac arrest after having fentanyl- transdermal system applied by her grandmother for pain relief. Details unknown (US)

11 Pediatric Adverse Events: Deaths (1 year post-exclusivity period; n=5) 4.16 year old male with history of drug abuse (marijuana, methylphenidate, dextropropoxyphene) reported to have been using the fentanyl transdermal system several days prior to death and was found wearing a 100  g/hr patch (US) 5.16 year old male with history of alcohol and marijuana use died from cardiac arrest after using 100  g/hr patches obtained from another student. He was found wearing a 100  g/hr patch. (US)

12 Non-Fatal Adverse Events (1 year post-exclusivity period; n=3) 1.Euphoria, hallucinations, and weight loss after initiation therapy with the fentanyl transdermal system 2.Withdrawal symptoms from a “loose” patch 3.Respiratory depression after intentional misuse of fentanyl patch

AdultApproval 2003PediatricExclusivity 4 pediatric deaths 5 pediatric deaths 1 year Post- exclusivity date 3 pediatric deaths 5/15/04 Pediatric Reported Deaths Since Approval Mandatory Reporting Period

14 AERS Pediatric Deaths Outside of the Exclusivity Reporting Period –Accidental exposure –Misuse or Abuse –Off-label use: Post-tonsillectomy and adenoidectomy pain Infectious mononucleosis and sore throat pain Chronic headaches and infectious mononucleosis Acute migraine –Rhabdomyosarcoma

15 Cumulative Pediatric AERS Database Reports for Fentanyl Transdermal System (n=35) Time PeriodTotal Number of Reports Received By FDA Reports By Indication Chronic Pain (deaths) NON-Chronic Pain* (deaths) 8/90 (approval date) - 1/28/ (1)5 (3) 1/29/03 – 2/29/04 (1 yr post-exclusivity period) 83 (1)5 (4) 3/1/04 – 4/30/0430 (0)3 (3) Totals3522 (2)13 (10) * No indication for chronic pain management identified in report

16 Comments Many of the pediatric adverse events captured occurred in patients who were administered the product for an unlabeled indication (e.g. treatment of acute pain in a non- opioid tolerant patient) Need for additional education regarding proper use of the fentanyl transdermal system to further minimize abuse, misuse, and off-label use